Helicobacter Pylori Resistance (CRIHEP)

University Hospital of North Norway

Status: Completed

Conditions: Helicobacter Pylori Resistance

Treatments: Drug: levofloxacin, amoxicillin, clarithromycin

Study type: Observational

Funder types: Other

Identifiers

NCT05019586

University Hosp North Norway

Details and patient eligibility

About

The main goal of the study was to characterize the morbidity, immunological, microbiolical and clinical phenotypes of patients with treated- resistance to Helicobacter pylori (HP) infection, and the effect of triple therapy including the levofloxacin. Control groups were newly diagnosed, previously infected and never infected HP patients

Full description

See Nestegard O, et al. PLOS ONE | https://doi.org/10.1371/journal.pone.0238944 September 23, 2020

Enrollment: 185 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients referred to a GI- unite with upper GI complains and performing an upper endoscopy -

Exclusion criteria

Patients with severe chronic diseases and not willing to participate

Trial design

185 participants in 4 patient groups

Helicobacter pylori resistance

Description:

Patients with treatment resistance to Helicobacter pylori treatment registered at GI-unites from 1990-2012 and included from 2010 to 2012. These patients were treated with a triple therapy of levofloxacin, amoxicillin and proton inhibitor for 10 days

Treatment:

Drug: levofloxacin, amoxicillin, clarithromycin

Newly diagnosed Helicobacter pylori

Description:

Patients with newly diagnosed Helicobacter pylori infection from 2010-2012.These patients were treated with a triple therapy of clarithromycin, amoxicillin and proton inhibitor for 10 days

Treatment:

Drug: levofloxacin, amoxicillin, clarithromycin

Previously eradicated Helicobacter pylori infection

Description:

Patients with previously Helicobacter pylori infection included from 2010-2012.

Never Helicobacter pylori infection

Description:

Patients with previously Helicobacter pylori infection included from 2010-2012.